NCT02100527View on ClinicalTrials.gov

Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Acne Vulgaris
Interventions
DRUG

PF-05175157

200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks

DRUG

Placebo

placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY